Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > PHIZER just bought Trillium ---for--

<< Previous

Bullboard Posts

Next >>

Comment by gojotv!on Aug 23, 2021 3:10pm

210 Views

Post# 33749515

RE:RE:PHIZER just bought Trillium ---for--

That's pretty impressive, since Trillium doesn't even have a working cure for cancer.
This supports my argument that Theralase shouldn't be sold cheap.
We have maybe the only effective approach to fight glioblastoma, an irregular-cell-shaped cancer that is impossible to remove surgically and which is proliferating with our modern cellphone use.
(Gordon Downie and Neil Peart both succumbed to this terrible disease.)
We have a solution against emerging viruses which could make global pandemics a thing of the past.
With our two-treatment, outpatient cancer solutions, we could empty all the hospital beds now occupied by cancer patients.
And so much more!
In short, TLD-1433 is the panacea worth trillions to the medical community and the world! If Trillium got nearly $20 for whatever it is they do, THeralase could surely be worth... at LEAST the same as "Apple" stock! With our way smaller share float? It's a no-brainer!
So, let's not sell out.
I want my millions in annual dividends, and so should you.
Don't let the manipulators get to you.
Think "Quahn!"

gojotv! wrote: What do I think?
I think that if I were a researcher for Big Pharma, I'd know that TLD-1433 is the talk of international academia in photo-dynamic therapy, with papers, lectures and mentions being churned out all over the globe.
...Not to mention its anti-viral applications, vital to the world-stopping, economy-destroying battles we face against Covid, Zika, Ebola, and so many more emerging "new" viruses.
THAT could be where the real money is made in the future.
So, as an agent of Big Pharma, I'd be sure to have a few guys posting regularly wherever shareholders gather to sound out their opinions on a future buyout, and to put rock-bottom price expectations out there.
Those agents would most likely have a strong pro-US bias and try to characterize Canadians as cute, ineffectual, and really lucky to get American handouts.
However, I'm not an agent of Big Pharma; I'm a Canadian investor, so I don't want a buyout.
I want Canada to develop its own BIG international Pharma-tech corporation to keep the money and talent in Canada. Also, I scoff at the suggestion of a buyout at anything less than $100US a share.
$178-200US is much more like it.
That's where my ears might start listening.
Maybe.
Because really, I'd rather live on the generous dividends my many shares will produce for me and generations to come while watching my Canada thrive at the foot of a burgeoning world corporation.
THAT, gentlemen, is the "Quahn".

HomerAndCompany wrote: $18.50/share, closing price was $6.09, so >200% premium.

Aug 23 (Reuters) - Trillium Therapeutics Inc:

* PFIZER TO ACQUIRE TRILLIUM THERAPEUTICS INC.

* TRILLIUM THERAPEUTICS INC - DEAL FOR IMPLIED EQUITY VALUE OF $2.26 BILLION

* TRILLIUM THERAPEUTICS INC - DEAL FOR $18.50 PER SHARE, IN CASH

* TRILLIUM THERAPEUTICS INC - PROPOSED DEAL OF TRILLIUM IS TO BE COMPLETED BY WAY OF A STATUTORY PLAN OF ARRANGEMENT UNDER BUSINESS CORPORATIONS ACT

* TRILLIUM THERAPEUTICS INC - COMPLETION OF ACQUISITION IS ALSO SUBJECT TO COURT AND REGULATORY APPROVAL, CERTAIN OTHER CONDITIONS Source text for Eikon: Further company coverage: